JPWO2022197756A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022197756A5 JPWO2022197756A5 JP2023557352A JP2023557352A JPWO2022197756A5 JP WO2022197756 A5 JPWO2022197756 A5 JP WO2022197756A5 JP 2023557352 A JP2023557352 A JP 2023557352A JP 2023557352 A JP2023557352 A JP 2023557352A JP WO2022197756 A5 JPWO2022197756 A5 JP WO2022197756A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- independently selected
- sulfur
- nitrogen
- oxygen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 46
- 150000001875 compounds Chemical class 0.000 claims 36
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 23
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 23
- 125000005842 heteroatom Chemical group 0.000 claims 23
- 229910052757 nitrogen Inorganic materials 0.000 claims 23
- 229910052760 oxygen Inorganic materials 0.000 claims 23
- 239000001301 oxygen Substances 0.000 claims 23
- 229910052717 sulfur Chemical group 0.000 claims 23
- 239000011593 sulfur Chemical group 0.000 claims 23
- 229920006395 saturated elastomer Polymers 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 125000001931 aliphatic group Chemical group 0.000 claims 7
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 5
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000002950 monocyclic group Chemical group 0.000 claims 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 3
- 125000002619 bicyclic group Chemical group 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 125000004980 cyclopropylene group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
- 206010019860 Hereditary angioedema Diseases 0.000 claims 1
- 102000003827 Plasma Kallikrein Human genes 0.000 claims 1
- 108090000113 Plasma Kallikrein Proteins 0.000 claims 1
- 201000011190 diabetic macular edema Diseases 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163162477P | 2021-03-17 | 2021-03-17 | |
| US63/162,477 | 2021-03-17 | ||
| PCT/US2022/020479 WO2022197756A1 (en) | 2021-03-17 | 2022-03-16 | Plasma kallikrein inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024510503A JP2024510503A (ja) | 2024-03-07 |
| JP2024510503A5 JP2024510503A5 (https=) | 2025-03-24 |
| JPWO2022197756A5 true JPWO2022197756A5 (https=) | 2025-03-24 |
Family
ID=81327137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023557352A Pending JP2024510503A (ja) | 2021-03-17 | 2022-03-16 | 血漿カリクレイン阻害剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240382482A1 (https=) |
| EP (1) | EP4308228A1 (https=) |
| JP (1) | JP2024510503A (https=) |
| CN (1) | CN117396474A (https=) |
| WO (1) | WO2022197756A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200143376A (ko) | 2018-03-13 | 2020-12-23 | 샤이어 휴먼 지네틱 테라피즈 인크. | 혈장 칼리크레인 억제제로서의 치환된 이미다조피리딘 및 이의 용도 |
| CN114667289B (zh) | 2019-09-18 | 2025-08-26 | 武田药品工业有限公司 | 杂芳基血浆激肽释放酶抑制剂 |
| EP4031547B1 (en) | 2019-09-18 | 2024-07-17 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof |
| CN117396473A (zh) * | 2021-03-17 | 2024-01-12 | 武田药品工业株式会社 | 血浆激肽释放酶的咪唑并吡啶基抑制剂 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| ATE141502T1 (de) | 1991-01-15 | 1996-09-15 | Alcon Lab Inc | Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US6887870B1 (en) * | 1999-10-12 | 2005-05-03 | Bristol-Myers Squibb Company | Heterocyclic sodium/proton exchange inhibitors and method |
| AU2008309517B2 (en) * | 2007-10-12 | 2013-03-14 | Astrazeneca Ab | Inhibitors of protein kinases |
| EP2627178B1 (en) * | 2010-10-11 | 2018-05-02 | Merck Sharp & Dohme Corp. | Quinazolinone-type compounds as crth2 antagonists |
| EP3087067B1 (en) * | 2013-12-26 | 2018-10-24 | Takeda Pharmaceutical Company Limited | 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (magl) inhibitors |
| CN106794181A (zh) * | 2014-06-04 | 2017-05-31 | 托马斯·黑勒戴药物研究基金会 | 用于治疗炎性和自身免疫性病况的mth1抑制剂 |
| WO2016010108A1 (ja) * | 2014-07-18 | 2016-01-21 | 塩野義製薬株式会社 | 含窒素複素環誘導体およびそれらを含有する医薬組成物 |
| WO2016201052A1 (en) | 2015-06-12 | 2016-12-15 | Global Blood Therapeutics, Inc. | Bridged bicyclic kallikrein inhibitors |
| IL263235B (en) | 2016-05-31 | 2022-07-01 | Kalvista Pharmaceuticals Ltd | History of pyrazoles as plasma kallikrein inhibitors |
| KR20200143376A (ko) * | 2018-03-13 | 2020-12-23 | 샤이어 휴먼 지네틱 테라피즈 인크. | 혈장 칼리크레인 억제제로서의 치환된 이미다조피리딘 및 이의 용도 |
-
2022
- 2022-03-16 US US18/550,571 patent/US20240382482A1/en active Pending
- 2022-03-16 EP EP22714694.1A patent/EP4308228A1/en active Pending
- 2022-03-16 CN CN202280033916.XA patent/CN117396474A/zh active Pending
- 2022-03-16 WO PCT/US2022/020479 patent/WO2022197756A1/en not_active Ceased
- 2022-03-16 JP JP2023557352A patent/JP2024510503A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5330324B2 (ja) | Ｆｐアゴニストとして有用な、芳香族のあるｃ１６〜ｃ２０が置換されたテトラヒドロプロスタグランジン類 | |
| US9611347B2 (en) | Catalysts and methods for ring opening metathesis polymerization | |
| US6649647B1 (en) | Trioxane derivatives | |
| JP5265518B2 (ja) | アルテミシニン誘導体の二量体、この調製およびこの治療上の使用 | |
| JPWO2022197756A5 (https=) | ||
| JPWO2021055621A5 (https=) | ||
| CA2685739C (en) | Hydroxy sulfonate of quinone compounds and their uses | |
| JPWO2022197758A5 (https=) | ||
| Böhn et al. | Solid-state photoreactivity of ortho-distyrylaromatic compounds | |
| Adam et al. | Cyclopropylcarbinyl ring opening as mechanistic probe for differentiation between the singlet and triplet spin states of trimethylenemethane diradicals (non-Kekule species) | |
| JPWO2022197763A5 (https=) | ||
| El Amoudi et al. | Photoreactivity of 2-and 3-substituted benzo [b] thiophene 1-oxides in solution | |
| JPWO2022197789A5 (https=) | ||
| US5817692A (en) | Endoperoxides useful as antiparasitic agents | |
| Trost et al. | New synthetic methods. Rational synthesis of 7, 8-diazatetracyclo [3.3. 0.02. 403.6] oct-7-ene | |
| JPWO2022197755A5 (https=) | ||
| JPH0356488A (ja) | 抗アテローム性動脈硬化症アザフロクロモン | |
| de Jong et al. | Phenylsylfonyl-substituted 5-alkoxy-2 (5H)-furanones; a new class of highly reactive chiral dienophiles. | |
| JPH02191271A (ja) | １，５―ベンゾオキサチエピン誘導体 | |
| Hirao et al. | Synthesis of 2, 9-dimethylditriaxane (2, 9-dimethylheptacyclo-[6.4. 0.0 2, 4. 0 3, 7. 0 5, 12. 0 6, 10. 0 9, 11] dodecane) | |
| Vionnet et al. | Regioselective Radical Additions to 7‐Oxabicyclo [2.2. 1] hept‐5‐en‐2‐one | |
| Christl et al. | Several polycyclic valence isomers of dimethyl [14] annulene-1, 8-dicarboxylate. Reactivity of a nonconjugated bis [bicyclo [1.1. 0] butane] | |
| Carretero et al. | New one-step process for the synthesis of functionalized 1, 6-dioxaspiro [4, 5] decanes | |
| NL8503213A (nl) | Prostaglandine-analogen, werkwijzen ter bereiding ervan alsmede farmaceutische preparaten, die de prostaglandine-analogen bevatten. | |
| Pyriadi et al. | Synthesis and free radical polymerization of N‐substituted citraconimides |